THOUSANDS OF BLOOD PRESSURE MEDICATION BOTTLES RECALLED NATIONWIDE AFTER QUALITY FAILURE
Macleods Pharma USA, a New Jersey-based pharmaceutical company, has initiated a nationwide recall of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets after the medication failed to meet federal quality standards, the U.S. Food and Drug Administration said.
The recall affects 3,528 30-count bottles from lot 12251163A and 216 90-count bottles from lot 12251163B. Both lots carry an expiration date of May 31, 2027.
The FDA classified the action as a Class II recall, meaning use of the affected medication "may cause temporary or medically reversible adverse health consequences" but the likelihood of serious health consequences is considered remote. The reason for the recall was "failed dissolution specifications," indicating the pills did not dissolve as required during testing.
Affected products can be identified by their National Drug Codes: 33342-246-07 for the 30-count bottles and 33342-246-10 for the 90-count bottles. The recall was initiated by Macleods Pharma USA on October 7 and was classified by the FDA on October 26.
The medication, used to treat high blood pressure, was distributed nationwide. This recall follows a similar action in September, when India-based Inventia Healthcare Ltd. recalled 13,567 bottles of 25-milligram chlorthalidone tablets after the medication also failed dissolution testing.
Consumers who have the affected medication are advised to check their prescription bottles for the lot numbers and National Drug Codes. Those in possession of the recalled products should consult their healthcare provider or pharmacist regarding appropriate next steps.
